These results are highly encouraging as they suggest that the modification of VLVs targeting human endogenous gammaretroviral Env on tumours may provide an effective new type of combination therapy for many patients with advanced malignancies unresponsive to CPI monotherapy. This evidence concerns the gene ERVW-1 and neoplasm.